Patents Examined by Oluwafemi Masha
-
Patent number: 8962665Abstract: The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or/and syk inhibitors.Type: GrantFiled: January 12, 2011Date of Patent: February 24, 2015Assignee: AB ScienceInventors: Alain Moussy, Abdellah Benjahad, Jason Martin, Emmanuel Chevenier, Didier Pez, Franck Sandrinelli, Willy Picoul
-
Patent number: 8916557Abstract: The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).Type: GrantFiled: April 18, 2012Date of Patent: December 23, 2014Assignee: Bayer Intellectual Property GmbHInventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Gerd Rühter, Carsten Schultz-Fademrecht, Dirk Kosemund, Philip Lienau
-
Patent number: 8912359Abstract: A method of combating infectious agents, such as Pneumocystis pneumonia, and a method of treating a subject in need of such treatment is disclosed. The method comprises administering to the subject a bis-benzamidoxime of formula I wherein the linker is a di-substituted cyclic moiety of any ring size and may contain at least one heteroatom; the aromatic group is 1,2-; 1,3-; or 1,4-disubstituted; R is selected from the group consisting of a hydrogen, a linear or branched alkyl group, containing from 1 to 20 carbon atoms; R? is selected from the group consisting of a hydrogen, a linear or branched alkyl group containing from one to twenty carbon atoms, an aromatic ring, a cycloalkyl group containing three to eight carbon atoms, or a hydroxyl group; alternatively, R and R? may form a cyclic structure that can be fused to another cyclic system; or a pharmaceutically acceptable salt thereof. Pharmaceutical formulations and active compounds useful in the practice of the present invention are also disclosed.Type: GrantFiled: March 17, 2011Date of Patent: December 16, 2014Assignees: University of Cincinnati, Xavier UniversityInventors: Peter D. Walzer, Melanie T. Cushion, Annie Mayence, Tien Liang Huang, Jean Jacques Vanden Eynde
-
Patent number: 8906893Abstract: The present invention relates to substances, to electroluminescent device comprising these substances, and to the use thereof.Type: GrantFiled: November 17, 2011Date of Patent: December 9, 2014Assignee: Merck Patent GmbHInventors: Rémi Manouk Anémian, Aurélie Ludemann, Thomas Eberle, Sigurd Hoeger, Eva Maria Reis, Vanessa Bobbe
-
Patent number: 8901127Abstract: The present invention relates to the compounds of general formula I wherein R1 and R2 are defined as described hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the medicaments containing the pharmacologically effective compounds, the preparation thereof and the use thereof.Type: GrantFiled: August 19, 2011Date of Patent: December 2, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Norbert Hauel, Raimund Kuelzer
-
Patent number: 8901142Abstract: The present invention relates to certain pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine and dipyrazolopyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine or dipyrazolopyrimidine compounds.Type: GrantFiled: July 20, 2012Date of Patent: December 2, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Zhaoyang Meng, M. Arshad Siddiqui, Panduranga Adulla P. Reddy, Mehul F. Patel, Yang Nan
-
Patent number: 8895729Abstract: Process methods for making the dual mTOR/PI3K inhibitor GDC-0980, named as (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one, having the structure: and stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof.Type: GrantFiled: October 9, 2013Date of Patent: November 25, 2014Assignee: Genentech, Inc.Inventors: Srinivasan Babu, Zhigang Cheng, Francis Gosselin, Pirmin Hidber, Ursula Hoffmann, Theresa Humphries, Reinhard Reents, Qingping Tian, Herbert Yajima
-
Patent number: 8889667Abstract: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.Type: GrantFiled: December 29, 2011Date of Patent: November 18, 2014Assignee: Agios Pharmaceuticals, IncInventors: Francesco G. Salituro, Jeffrey Saunders, Shunqi Yan
-
Patent number: 8889858Abstract: As a novel substance having a novel skeleton, provided is a novel phosphorescent organometallic iridium complex that can emit phosphorescence in a blue green to red wavelength region and has high emission efficiency. The phosphorescent organometallic iridium complex has a ligand having a pyridyl pyrimidine skeleton, i.e., the phosphorescent organometallic iridium complex has a ligand having a structure represented by the following general formula (G0). Note that in the formula, R1 and R4 to R6 separately represent hydrogen or an alkyl group having 1 to 6 carbon atoms; and R2 and R3 separately represent any of hydrogen, an alkyl group having 1 to 6 carbon atoms, a phenyl group that may have a substituent, and a pyridyl group that may have a substituent.Type: GrantFiled: April 11, 2013Date of Patent: November 18, 2014Assignee: Semiconductor Energy Laboratory Co., Ltd.Inventors: Hideko Inoue, Tomoka Nakagawa, Tomoya Yamaguchi, Hiromi Seo, Satoshi Seo
-
Patent number: 8865711Abstract: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.Type: GrantFiled: February 3, 2012Date of Patent: October 21, 2014Assignee: H. Lundbeck A/SInventors: Andreas Ritzén, Jan Kehler, Morten Langgård, Jacob Nielsen, John Paul Kilburn, Mohamed M. Farah
-
Patent number: 8859584Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.Type: GrantFiled: December 17, 2012Date of Patent: October 14, 2014Assignee: AbbVie, Inc.Inventors: Kevin R. Woller, Gregory A. Gfesser, Huaqing Liu, Jerome F. Daanen, Eric A. Voight, Irene I. Drizin, Anurupa Shrestha, Kathleen H. Mortell, Philip R. Kym, Michael E. Kort, Arthur Gomtsyan
-
Patent number: 8853249Abstract: The present invention relates to an improved method for the synthesis of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof.Type: GrantFiled: December 14, 2010Date of Patent: October 7, 2014Assignees: Helmholtz-Zentrum für Infektionsforschungs GmbH, Medizinische Hochschule Hannover, Gottfried Wilhelm Leibniz UniversitätInventors: Markus Kalesse, Ulrike Eggert
-
Patent number: 8846935Abstract: Herein are disclosed indazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.Type: GrantFiled: May 5, 2011Date of Patent: September 30, 2014Assignee: GlaxoSmithKline LLCInventors: Celine Duquenne, Neil Johnson, Steven D. Knight, Louis Lafrance, William H. Miller, Kenneth Newlander, Stuart Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
-
Patent number: 8841311Abstract: The present invention relates to sulphone-substituted quinazoline derivatives of the formula (I), processes for their preparation and their use as a medicament for the treatment of various diseases.Type: GrantFiled: July 18, 2009Date of Patent: September 23, 2014Assignee: Bayer Intellectual Property GmbHInventors: Bernd Buchmann, Dirk Kosemund, Duy Nguyen, Arne Von Bonin
-
Patent number: 8829012Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.Type: GrantFiled: January 23, 2014Date of Patent: September 9, 2014Assignee: G1 Therapeutics, Inc.Inventors: Francis X. Tavares, Jay C. Strum
-
Patent number: 8822683Abstract: Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.Type: GrantFiled: January 23, 2014Date of Patent: September 2, 2014Assignee: G1 Therapeutics, Inc.Inventors: Francis X. Tavares, Jay C. Strum
-
Patent number: 8809353Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: March 18, 2008Date of Patent: August 19, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Dean Wilson, Lev T. D. Fanning, Paul Krenitsky, Andreas Termin, Pramod Joshi, Urvi Sheth
-
Patent number: 8809547Abstract: The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests, including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation.Type: GrantFiled: July 4, 2009Date of Patent: August 19, 2014Assignee: Bayer CropScience AGInventors: Thomas Bretschneider, Eva-Maria Franken, Ulrich Görgens, Martin Füβlein, Achim Hense, Joachim Kluth, Hans-Georg Schwarz, Adeline Köhler, Olga Malsam, Arnd Voerste, Angela Becker
-
Patent number: 8809336Abstract: The invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N?C(R6), (R7)C?N, (R8)N—C(O), (R8)2C—C(O), N?N or (R7)C?C(R6); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Q1 is a bond or a saturated C1-3 hydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONRq or NRqCO where Rq is hydrogen or methyl, or Rq is a C1-4 alkylene chain linked to R1 or a carbon atom of Q1 to form a cyclic moiety; and wherein the carbon atoms of the linker group Q1 may optionally bear one or more substituents selected from fluorine and hydroxy; Q2 is a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of theType: GrantFiled: September 4, 2013Date of Patent: August 19, 2014Assignees: Astex Therapeutics Limited, The Institute of Cancer Research: Royal Cancer Hospital, Cancer Research Technology LimitedInventors: Valerio Berdini, Robert George Boyle, Gordon Saxty, David Winter Walker, Steven John Woodhead, Paul Graham Wyatt, Alastair Donald, John Caldwell, Ian Collins, Tatiana Faria Da Fonseca
-
Patent number: 8809328Abstract: An object of the present invention is to provide a compound that can regulate plant growth. The compound selected from the group consisting of (A) and (B): (A) 3H-imidazo[4,5-d][1,2,3]triazin-4,6(5H,7H)-dione; and (B) 3-methyl-3H-imidazo[4,5-d][1,2,3]triazin-4,6(5H,7H)-dione; has a plant growth regulating action.Type: GrantFiled: April 24, 2012Date of Patent: August 19, 2014Assignee: National University Corporation Shizuoka UniversityInventors: Hirokazu Kawagishi, Jae-Hoon Choi